$27.440
-1.114 (-4.06%)Zum Schluss
MAZE-News
MAZE-Events
Maze CEO Discusses Progress on MZE782 and MZE829 Clinical Trials
"The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in 2027, and continued strong enrollment in the Phase 2 HORIZON trial of MZE829 across three cohorts with additional data on track for 10-15 patients per cohort in late 2026 or early 2027," said Jason Coloma, chief executive officer of Maze. "Looking ahead, we continue to prepare for the pivotal trial of MZE829. We are also advancing MZE782 toward a Phase 2 trial in CKD, which we expect to initiate in the first half of next year. With a strong balance sheet and expected cash runway into 2029, we are well positioned to execute against the clinical milestones in our pipeline."
Maze Reports Q1 Revenue of $20M, Exceeds Expectations
Reports Q1 revenue $20M, consensus $8.5M. License revenue was $20M for Q1. No license revenue was recognized for the quarter ended March 31, 2025. License revenue recognized in Q1 of 2026 reflects the achievement of a milestone pursuant to the exclusive license agreement with Shionogi & Co. for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup. Cash, cash equivalents and marketable securities were $362.9M as of March 31, compared to $360.0M as of December 31, 2025. Maze expects that its cash, cash equivalents and marketable securities as of March 31, together with the proceeds from the registered offering completed in April and a $20M milestone payment received from Shionogi & Co. in April, will fund operations into 2029 based on its current business plan.
Leerink Partners Acts as Sole Underwriter for Healthcare Fund Offering
The offering includes participation from both new and existing investors including Farallon Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a large U.S.-based healthcare-focused fund, a leading mutual fund, Frazier Life Sciences, Janus Henderson Investors, Deep Track Capital, and Driehaus Capital Management, as well as other healthcare dedicated funds. Leerink Partners LLC is acting as sole underwriter for the proposed offering.
Major Averages Rise on U.S. Iran Peace Plan
The major averages closed broadly higher following reports that the U.S. has provided a plan to Iran to bring the war to an end, which sent oil prices lower. The Associated Press reported that Iran was given a 15-point proposal from the U.S. to end the conflict, though media have reported that the two sides remain far apart on a resolution and attacks from both sides have continued.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:MerckTerns Pharmaceuticalsfor $53 per share in cashElon Musk's SpaceX will file an IPO prospectus as soon as this week or next,Armexpectsfrom its chips unit in five yearsChewyreportedand provided its outlook for Q1 and FY26JetBlueis exploring a potential merger with rivals,2. WALL STREET CALLS:Armto Outperform from Market Perform at Raymond JamesWolfeGeneral Motorson underappreciated potential tailwindsWedbushRezoluteas worst case scenario seems unlikely for cHIMondelezto Neutral from Buy at Rothschild & Co RedburnEVgowith Neutral from Overweight at JPMorgan3. AROUND THE WEB:Salesforceis skipping raises for its director-level and above employees, Insider reportsA jury found Metaand Googleliable in a social media addiction trial, Reuters saysMeanwhile, Metawill lay off "a few hundred people" across the company on Wednesday, The Information saysSK Hynixplans to spend about $8B on cutting-edge EUV lithography chipmaking tools from ASMLthrough 2027, Bloomberg saysInteland AMDhave each told customers they plan to raise prices across their entire CPU product lines starting in March and April, Nikkei reports4. MOVERS:Sareptarose after announcingfrom Phase 1/2 ascending dose studies of SRP-1001 and SRP-1003Brazegained afterand authorizing a stock repurchase program of up to $100MApogee Therapeuticsfinished higher after announcing aMaze Therapeuticsclosed lower afterand announcing data from its Phase 2 HORIZON trialAdma Biologicsfell for another session afterfrom Culper Research5. EARNINGS/GUIDANCE:Paychexand reaffirmed its guidance for FY26EDAP TMSand backed its guidance for FY26Cognyte, with EPS beating consensusCintasand raised its guidance for FY26QT Imagingand reaffirmed guidance for FY26INDEXES:The Dow rose 305.43, or 0.66%, to 46,429.49, the Nasdaq gained 167.93, or 0.77%, to 21,929.83, and the S&P 500 advanced 35.53, or 0.54%, to 6,591.90.
Maze Therapeutics Shares Down 29.8% to $34.40
Maze Therapeutics is down -29.8%, or -$14.60 to $34.40.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.